Vanderbilt Vascular Medicine Conference - 12/1/2021

Wednesday, December 1, 2021, 8:00 AM - 9:00 AM, Online

AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Attendance (1.00 hours)

The Vanderbilt Vascular Medicine Conference is a weekly educational series run by the Vascular Medicine Section. Topics include case discussion, journal club, and didactic sessions in the field of vascular medicine.

Objective(s): 1 1. Describe and discuss 2 a. The disease process of vascular disorders. 3 b. The indications, contraindications, complications and limitations of appropriate vascular medicine diagnostics (imaging studies and laboratory tests) 4 c. The basic pathophysiology and approach to vascular disorders. 5 2. Demonstrate the ability to take a pertinent cardiovascular history and perform a focused physical examination 6 3. Interpret the results of laboratory tests and imaging studies administered to patients with suspected vascular disorders 7 4. Determine whether medical treatment or interventional/surgical referral is appropriate for patients based on the patients diagnoses. 8 5. Use the most recent evidence based approaches to evaluate, diagnose, and manage patients with vascular disorders
Location: Online
Specialties: Medicine, Nursing

Faculty Disclosures:
Aaron W Aday, MD (Consulting Fee-OptumCare-Relationship_has_not_ended - 10/20/2021)
Joshua A Beckman, MD (Amgen-Consulting Fee-Consulted on Evolocumab for PAD-Evolocumab-PAD-Option_2-Option_2-Low, but possible. |JanOne-Consulting Fee-Steering Committee for a clinical trial-Nitrite derivative-Limb neuropathic pain-Option_2-Option_1-No risk. |Janssen-Consulting Fee-I am on a DSMB-Rivaroxaban-COVID-Option_2-Option_2-Possible if I speak about PAD|Contracted Research-CML drug-Novartis AG-None-CML-Option_2-Option_1-I am on a DSMB|Novo Nordisk-Contracted Research-Enrolling in a clinical trial-Semaglutide-Diabetes and PAD-Option_2-Option_1 Option_2-The medication already has FDA approval for cardiovascular endpoints in diabetes, so I would guess high.|Boston Scientific Corporation-Contracted Research-Enrolling in a clinical trial about pulmonary embolism-Catheter directed thrombolysis for PE-Pulmonary Embolism-Option_2-Option_2-High. It is a standard use device with FDA approval and CMS coverage|Bristol-Myers Squibb-Company-Supported Research-Investigator initiated grant on emergency room management of low-risk pulmonary embolism-Management of PE. They make an anticoagulant, apixaban.-Pulmonary embolism. -Option_2-Option_2-High. This kind of work has been published. - 08/04/2021)
Soo H Kim, MD (One day advisory board for the company-celiprolol-vascular Ehlers Danlos-Option_2-Option_1-the drug is approved for use in Europe so there is likelihood it would be used during discussed during CME activities - 07/21/2021)
Alexandra M Moran, APRN (Nothing to disclose - 10/25/2021)

1. 1. Describe and discuss
2. a. The disease process of vascular disorders.
3. b. The indications, contraindications, complications and limitations of appropriate vascular medicine diagnostics (imaging studies and laboratory tests)
4. c. The basic pathophysiology and approach to vascular disorders.
5. 2. Demonstrate the ability to take a pertinent cardiovascular history and perform a focused physical examination
6. 3. Interpret the results of laboratory tests and imaging studies administered to patients with suspected vascular disorders
7. 4. Determine whether medical treatment or interventional/surgical referral is appropriate for patients based on the patients diagnoses.
8. 5. Use the most recent evidence based approaches to evaluate, diagnose, and manage patients with vascular disorders